Comparative Genomic Profiling of Lung Adenocarcinoma in Asians and Caucasians: A Propensity Matched Analysis

Adenocarcinoma of Lung Clinical Trial

Official title:

Comparative Genomic Profiling of Lung Adenocarcinoma in Asians and Caucasians: A Propensity Matched Analysis

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04692935
• Other study ID #: 2020PHB375
• Status: Not yet recruiting
• Start date: January 2021
• Est. completion date: December 2021

Study information

• Verified date: January 2021
• Source: Peking University People's Hospital
• Contact: Jian Zhou, MD
• Phone: 010-88326650
• Email: zhoujianmd[@]hotmail.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Lung adenocarcinomas (LUADs) from Asian ancestry are reported to have different genomic architectures compared with LUADs from Caucasian ancestry. However, due to lack of available cases, few studies controlled the clinical attributes during the comparisons of the genomic alterations. In this study, the investigators will identify Asian LUADs patients who had broad-panel next-generation sequencing (NGS) performed on their primary tumor between January 2018 and December 2019 at the department of thoracic surgery of Peking University People's Hospital. Then, Caucasian LUADs patients who had targeted NGS (Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets [MSK-IMPACT]) will be identified in the GENIE database, which consists of 6673 primary lung adenocarcinoma samples with clinical annotations. Finally, genomic alterations regarding somatic mutations, copy number variations, fusions, mutational signatures, oncogenic pathways, and therapeutic actionability will be comprehensively compared between these two cohorts after adjusting age, sex, smoking status, and pathologic stage using propensity score matching. This study will elucidate important ancestry differences between Asian and Caucasian lung adenocarcinoma patients.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 450
• Est. completion date: December 2021
• Est. primary completion date: July 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

• Primary lung adenocarcinoma

• Broad-panel next-generation sequencing

• Asian

Exclusion Criteria:

• Inadequate clinicopathological information

• Low-quality next-generation sequencing

Related Conditions & MeSH terms

• Adenocarcinoma
• Adenocarcinoma of Lung

Locations

Country	Name	City	State
n/a

Sponsors (3)

Lead Sponsor	Collaborator
Jun Wang	Berry Genomics Co., Ltd., Memorial Sloan Kettering Cancer Center

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Oncoprint of somatic mutations	Association between genomic features and race	July 2021
Primary	Copy number variations (CNVs)	CNVs analysis by race	July 2021
Primary	Mutational signatures	Analysis of mutational signatures by race	August 2021
Primary	Oncogenic pathways	Analysis of oncogenic pathways by race	September 2021
Primary	Therapeutic actionability	Analysis of actionable alterations by race	October 2021